title: Investigations into the stabilisation of drugs by sugar glasses: II. Delivery of an inulin-stabilised alkaline phosphatase in the intestinal lumen via the oral route.
abstract: In this study the possibility to deliver the acid-sensitive enzyme alkaline phosphatase (AP) from calf intestine (CIAP) to the intestinal system by oral administration was investigated. Tablets were prepared and in vitro evaluated. Final proof of concept studies were performed in rats. This acid labile enzyme is potentially useful in the treatment of sepsis, a serious condition during which endotoxins can migrate into the blood stream. The CIAP was freeze-dried with inulin and subsequently compacted into round biconvex tablets with a diameter of 4mm and a weight of 25-30 mg per tablet. The tablets were coated with an enteric coating in order to ensure their survival in the stomach. In vitro evaluation of tablets containing alkaline phosphatase from bovine intestine (BIAP) was the first step in the development. It was found that tablets without enteric coating dissolved rapidly in 0.10 M HCl with total loss of enzymatic activity of the alkaline phosphatase. Tablets that were coated were stable for at least 2 h in 0.10 M HCl, but dissolved rapidly when the pH was increased to 6.8. Furthermore, it was shown that the enzymatic activity of the released BIAP was fully preserved. The in vivo test clearly showed that the oral administration of enteric coated tablets resulted in the release of enzymatically active CIAP in the intestinal lumen of rats. The location of the enhanced enzymatic activity of AP in the intestines varied with the time that had passed between the administration of the tablets and the sacrificing of the rats. Also, the level of enzymatic activity increased with an increasing number of tablets that were administered.
authors.affiliation: Department of Pharmaceutical Technology and Biopharmacy, University of Groningen, A. Deusinglaan 1, 9713 AV Groningen, The Netherlands. j.c.eriksson@farm.rug.nl
authors.forename: H J C
authors.initials: HJ
authors.lastname: Eriksson
authors.forename: W R
authors.initials: WR
authors.lastname: Verweij
authors.forename: K
authors.initials: K
authors.lastname: Poelstra
authors.forename: W L J
authors.initials: WL
authors.lastname: Hinrichs
authors.forename: G J
authors.initials: GJ
authors.lastname: de Jong
authors.forename: G W
authors.initials: GW
authors.lastname: Somsen
authors.forename: H W
authors.initials: HW
authors.lastname: Frijlink
mesh_terms: D000284:Administration, Oral; D000469:Alkaline Phosphatase / Q000008:administration & dosage* / Q000737:chemistry; D000818:Animals; D003956:Dialysis; D004795:Enzyme Stability; D005612:Freeze Drying; D007413:Intestinal Mucosa / Q000378:metabolism*; D007444:Inulin / Q000008:administration & dosage*; D008297:Male; D051381:Rats; D017208:Rats, Wistar; D012995:Solubility; D013607:Tablets
chemical_list: D013607:Tablets; D007444:Inulin; D000469:Alkaline Phosphatase